The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine resistance before disease progression in HR-positive, HER2-negative advanced breast cancer.

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line treatment of individuals with hormone receptor (HR)-positive,

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company's pipeline.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an emergent ESR1 mutation to receive either AZ’s candidate or an aromatase inhibitor (anastrozole or letrozole), both taken alongside a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib).

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the first-line treatment of hormone receptor-positive,

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment, the company said.

AstraZeneca Plc’s experimental breast cancer pill helped patients live for longer without their disease worsening, the UK drugmaker said.